EA033921B9 - Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа - Google Patents

Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа

Info

Publication number
EA033921B9
EA033921B9 EA201891072A EA201891072A EA033921B9 EA 033921 B9 EA033921 B9 EA 033921B9 EA 201891072 A EA201891072 A EA 201891072A EA 201891072 A EA201891072 A EA 201891072A EA 033921 B9 EA033921 B9 EA 033921B9
Authority
EA
Eurasian Patent Office
Prior art keywords
acid derivatives
influenza viral
sialic acid
viral infections
treating influenza
Prior art date
Application number
EA201891072A
Other languages
English (en)
Other versions
EA201891072A1 (ru
EA033921B1 (ru
Inventor
Бетти Джин
Е-Лин Сиа
Пол Артур Джонс
Питер Джеймс Дженкинс
Генри Кеннет Уиндл
Вэнь Ян Ву
Original Assignee
Острэлиан Байомедикал Ко. Пти Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2015904895A external-priority patent/AU2015904895A0/en
Application filed by Острэлиан Байомедикал Ко. Пти Лтд filed Critical Острэлиан Байомедикал Ко. Пти Лтд
Publication of EA201891072A1 publication Critical patent/EA201891072A1/ru
Publication of EA033921B1 publication Critical patent/EA033921B1/ru
Publication of EA033921B9 publication Critical patent/EA033921B9/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6839—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses
    • A61K47/6841—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting material from viruses the antibody targeting a RNA virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06104—Dipeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0819—Tripeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1021—Tetrapeptides with the first amino acid being acidic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyrane Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Materials For Medical Uses (AREA)
  • Medicinal Preparation (AREA)

Abstract

Согласно изобретению предложены соединения общей формулы (I)где R, R, R, L, L, B, C и p являются такими, как определено в формуле изобретения, и их применение в изготовлении лекарственного средства для лечения или предупреждения инфекции, вызываемой вирусом гриппа. Предложены также фармацевтически приемлемые соли, сложные эфиры и стереоизомеры соединений.
EA201891072A 2015-11-20 2016-11-16 Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа EA033921B9 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AU2015904895A AU2015904895A0 (en) 2015-11-20 Compounds for medicinal applications
PCT/AU2016/051100 WO2017083914A1 (en) 2015-11-20 2016-11-16 Compounds for medicinal applications

Publications (3)

Publication Number Publication Date
EA201891072A1 EA201891072A1 (ru) 2018-11-30
EA033921B1 EA033921B1 (ru) 2019-12-10
EA033921B9 true EA033921B9 (ru) 2020-01-22

Family

ID=58717109

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891072A EA033921B9 (ru) 2015-11-20 2016-11-16 Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа

Country Status (19)

Country Link
US (1) US11007274B2 (ru)
EP (1) EP3377487B1 (ru)
JP (1) JP7034913B2 (ru)
KR (1) KR20180083402A (ru)
CN (1) CN108473483B (ru)
AU (1) AU2016356726C1 (ru)
BR (1) BR112018010027A2 (ru)
CA (1) CA3005774C (ru)
EA (1) EA033921B9 (ru)
ES (1) ES2911027T3 (ru)
IL (1) IL259425B (ru)
MX (1) MX2018005999A (ru)
MY (1) MY195168A (ru)
PH (1) PH12018501076A1 (ru)
SG (1) SG11201803962WA (ru)
TW (1) TWI742015B (ru)
UA (1) UA126654C2 (ru)
WO (1) WO2017083914A1 (ru)
ZA (1) ZA201803214B (ru)

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055149A1 (en) * 1999-03-12 2000-09-21 Biota Scientific Management Pty. Ltd. Dimeric compounds and as inhibitors of neuraminidase
WO2002020514A1 (en) * 2000-09-08 2002-03-14 Biota Scientific Management Pty Ltd Multivalent neuraminidase inhibitor conjugates
WO2003040138A1 (en) * 2001-11-09 2003-05-15 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
WO2013155375A1 (en) * 2012-04-14 2013-10-17 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2015011441A1 (en) * 2013-07-24 2015-01-29 University Of East Anglia Virus detection
CN105085455A (zh) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 唾液酸类似物或其药学上可接受的盐及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US6680054B1 (en) 1996-11-14 2004-01-20 Biota Scientific Management Pty Ltd. Macromolecular neuraminidase-binding compounds
DE102004002132A1 (de) 2004-01-15 2005-08-11 Man Roland Druckmaschinen Ag Einrichtung zur Erzeugung einer Beschichtung von Druckprodukten einer Druckmaschine
JP5950390B2 (ja) 2012-03-26 2016-07-13 国立大学法人 琉球大学 新規ミモシン誘導体

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000055149A1 (en) * 1999-03-12 2000-09-21 Biota Scientific Management Pty. Ltd. Dimeric compounds and as inhibitors of neuraminidase
WO2002020514A1 (en) * 2000-09-08 2002-03-14 Biota Scientific Management Pty Ltd Multivalent neuraminidase inhibitor conjugates
WO2003040138A1 (en) * 2001-11-09 2003-05-15 Biota Scientific Management Pty Ltd Dimeric compounds and their use as anti-viral agents
WO2013155375A1 (en) * 2012-04-14 2013-10-17 Academia Sinica Enhanced anti-influenza agents conjugated with anti-inflammatory activity
WO2015011441A1 (en) * 2013-07-24 2015-01-29 University Of East Anglia Virus detection
CN105085455A (zh) * 2014-05-13 2015-11-25 中国科学院广州生物医药与健康研究院 唾液酸类似物或其药学上可接受的盐及其应用

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
ROY, R. et al., "Solid-phase Synthesis of Dendritic Sialoside Inhibitors of Influenza A Virus Haemagglutinin", Journal of the Chemical Society, Chemical Communications, 1993, p. 1869-1872, Title; scheme 1-2; Experimental; Compounds 8-17; Scheme 1, p. 1871; Fig. 1 and final paragraph, p. 1872 *
ROYTMAN, R. et al., "Exploring the self-assembly of glycopeptides using a diphenylalanine scaffold", Organic & Biomolecular Chemistry, 2011, vol. 9, p. 5755-5761, Compound 5, Fig. 1, p. 5755; Nanostructure sample preparation and imaging, p. 5760 *
WATSON, K.G. et al., "Highly potent and long-acting trimeric and tetrameric inhibitors of influenza virus neuraminidase", Bioorganic & Medicinal Chemistry Letters, 2004, vol. 14, p. 1589-1592, Abstract; Table 2, p. 1590, Compounds 6-11; Table 1, p. 1590; tables 3a and 3b, p. 1591 *
ZANINI, D. et al., "Synthesis of New α-Thiosialodendrimers and Their Binding Properties to the Sialic Acid Specific Lectin from Limax flavus", Journal of the American Chemical Society, 1997, vol. 119, p. 2088-2095, Abstract; Introduction; Formulae 31-34, chart 1, p. 2092; Table 1, p. 2093 *

Also Published As

Publication number Publication date
ES2911027T3 (es) 2022-05-17
AU2016356726A1 (en) 2018-06-07
MY195168A (en) 2023-01-11
EA201891072A1 (ru) 2018-11-30
BR112018010027A2 (pt) 2018-11-21
AU2016356726C1 (en) 2021-12-09
NZ742593A (en) 2023-08-25
WO2017083914A1 (en) 2017-05-26
PH12018501076A1 (en) 2019-01-28
IL259425A (en) 2018-07-31
MX2018005999A (es) 2018-11-22
JP7034913B2 (ja) 2022-03-14
ZA201803214B (en) 2019-07-31
EA033921B1 (ru) 2019-12-10
KR20180083402A (ko) 2018-07-20
SG11201803962WA (en) 2018-06-28
TWI742015B (zh) 2021-10-11
US11007274B2 (en) 2021-05-18
EP3377487A4 (en) 2019-07-17
AU2016356726B2 (en) 2021-02-25
IL259425B (en) 2021-10-31
JP2019502662A (ja) 2019-01-31
EP3377487A1 (en) 2018-09-26
US20180264128A1 (en) 2018-09-20
CA3005774A1 (en) 2017-05-26
TW201726641A (zh) 2017-08-01
CA3005774C (en) 2024-01-09
UA126654C2 (uk) 2023-01-11
CN108473483B (zh) 2022-08-30
CN108473483A (zh) 2018-08-31
EP3377487B1 (en) 2022-01-12

Similar Documents

Publication Publication Date Title
PH12020551089A1 (en) Pyrrolopyrimidine compounds used as tlr7 agonist
PH12016501750A1 (en) Human plasma kallikrein inhibitors
MX2022007915A (es) Compuestos de benzopirazol y analogos de estos.
NZ732391A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12015501881B1 (en) Amide compounds for the treatment of hiv
PH12016501355A1 (en) Bicyclic heterocyclic derivatives as bromodomain inhibitors
NZ735575A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
EA201791515A1 (ru) Соединения пиразина для лечения инфекционных заболеваний
PH12018500065A1 (en) Oxysterols and methods of use thereof
PH12018500061A1 (en) Oxysterols and methods of use thereof
NZ631726A (en) Therapeutic compounds for the treatment of viral infections
MX2017010506A (es) Nuevo derivado de quinoleina para usarse en el tratamiento y prevencion de infecciones virales.
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
NZ709260A (en) Polycyclic-carbamoylpyridone compounds and their pharmaceutical use
PH12018500576A1 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
WO2013160810A3 (en) Novel betulinic acid derivatives as hiv inhibitors
NZ703064A (en) Inhibitors of hepatitis c virus
NZ741318A (en) Compound for treating or preventing hyperuricemia or gout
MX2021010297A (es) Inhibidores de calicreina plasmatica humana.
EA033921B9 (ru) Производные сиаловой кислоты и их применение в лечении инфекций, вызываемых вирусом гриппа

Legal Events

Date Code Title Description
TH4A Publication of the corrected specification to eurasian patent
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG TJ TM